Current Report Filing (8-k)
December 29 2014 - 4:35PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
December 19, 2014
Northwest Biotherapeutics, Inc.
(Exact name of registrant as specified in
its charter)
Delaware |
001-35737 |
94-3306718 |
(State or other jurisdiction |
(Commission |
(IRS Employer |
of incorporation or organization) |
File Number) |
Identification No.) |
4800 Montgomery Lane, Suite 800
Bethesda, Maryland 20814
(Address of Principal Executive Offices)
(240) 497-9024
(Registrant’s telephone number, including
area code)
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions
A.2 below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02. | Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. |
(e) At the 2014 annual meeting
of stockholders of Northwest Biotherapeutics, Inc. (the “Company”), the stockholders approved two matters:
the election of two Directors, and ratification of the appointment of Marcum LLP as the Company’s registered
independent public accountants for 2014. The stockholders also approved two additional matters on an advisory basis: the
Company’s executive compensation arrangements, and the frequency of future stockholder votes, on an advisory basis, on
the Company’s executive compensation arrangements.
The Company had recommended that stockholders vote “For”
the election of the Directors and the appointment of Marcum. The Company had also recommended that stockholders provide an
advisory vote “For” the Company’s executive compensation arrangements, and “For” future
shareholder votes, on an advisory basis, on the Company’s compensation arrangements to take place once every three (3)
years. The stockholders voted in favor of the Company’s recommendations on all four matters.
| Item 5.07. | Submission of Matters to a Vote of Security Holders. |
The Company’s 2014 annual meeting
of stockholders was held on December 19, 2014. At the meeting, the stockholders voted on two matters: the election of Mr. Bob Farmer
and Mr. Jerry Jasinowski as Class II members of the Board of Directors for a three-year term, and ratification of the appointment
of Marcum LLP as the Company’s registered independent
public accountants for 2014. The stockholders also voted, on an advisory basis, on two additional matters:
approval of the Company’s executive compensation arrangements and approval of the frequency of future stockholder votes,
on an advisory basis, on the Company’s executive compensation arrangements.
The stockholders voted in favor of the Company’s
recommendations on all four matters, as follows.
The stockholders approved the election of
Mr. Bob Farmer as a Class II Director for a term expiring at the annual meeting of stockholders in 2017, based upon the following
votes:
Member |
For |
Withheld |
Broker Non-Votes |
Mr. Bob Farmer |
33,299,067 |
1,556,693 |
18,021,658 |
The stockholders approved the election of
Mr. Jerry Jasinowski as a Class II Director for a term expiring at the annual meeting of stockholders in 2017, based upon the following
votes:
Member |
For |
Withheld |
Broker Non-Votes |
Mr. Jerry Jasinowski |
33,315,939 |
1,539,821 |
18,021,658 |
The stockholders ratified the appointment
of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2014,
based upon the following votes:
For |
Against |
Abstain |
Broker Non-Votes |
52,175,637 |
301,660 |
400,121 |
— |
The stockholders approved, on an advisory
basis, the Company’s executive compensation arrangements based upon the following votes:
For |
Against |
Abstain |
Broker Non-Votes |
34,263,783 |
438,627 |
153,350 |
18,021,658 |
The stockholders approved, on an advisory
basis, future stockholder votes, on an advisory basis, on the Company’s executive compensation arrangements once every three
years, based upon the following votes:
Every Three Years |
Every Two Years |
Every Year |
Abstain |
Broker Non-Votes |
30,531,167 |
242,622 |
3,836,144 |
245,827 |
18,021,658 |
In accordance with the stockholders’
recommendation, the Company’s Board of Directors has decided to include a stockholder vote, on an advisory basis, on executive
compensation in its proxy materials once every three years, with the next such advisory vote occurring in 2017.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
NORTHWEST BIOTHERAPEUTICS, INC. |
|
|
|
|
Date: December 29, 2014 |
By: |
/s/ Linda Powers |
|
|
Name: |
Linda Powers |
|
Title: |
Chief Executive Officer and Chairman |
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Apr 2023 to Apr 2024